Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption.
Eiling
Elisabeth
E
Brandt
Michael
M
Schwarz
Thomas
T
Hauschild
Axel
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068818:Cetuximab; D003082:Colectomy; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000601:surgery; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D012871:Skin Diseases / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D016559:Tacrolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; C117268:pimecrolimus; D000068818:Cetuximab; D016559:Tacrolimus